Nomination committee's proposal to the annual general meeting 2011 (revised version)

The nomination committee of Swedish Orphan Biovitrum AB (publ), which consists of Bo Jesper Hansen (chairman of the board of directors), Petra Hedengran (representing Investor and chairman of the Nomination Committee), Roger Johanson (Skandia Liv) and Åsa Nisell (representing Swedbank Robur Fonder), together representing approximately 49 per cent of the votes of all shares in the company. The nomination committee proposes, revising the proposal published on March 29, 2011,:

- that Claes Beyer from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting,
- that fees to be paid to the board of directors should be allocated with SEK 250,000 to each board member except for the chairman of the board of directors who shall not receive any fee for his board assignment, nor any fee for his committee work, that fees for work in the audit committee should be SEK 75,000 to the chairman and SEK 40,000 to each other member of such committee, that no fees should be paid for work in the compensation & benefit committee and that fees for work in the science committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee,
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice,
- that six ordinary board members without deputies should be appointed,
- that the board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson and Hans Wigzell should be re-elected, that Hans GCP Schikan and Helena Saxon should be elected as new board members and that Bo Jesper Hansen should be appointed chairman of the board of directors. Wenche Rolfsen, Michael Steinmetz and Hans Glemstedt have declined re-election, and
- that PricewaterhouseCoopers AB should be elected as the auditor of the company for the time until the end of the annual general meeting 2012.

The nomination committee in April 2011